WASHINGTON (Reuters) - U.S. officials are investigating if a Sanofi-Aventis meningitis vaccine may have caused five cases of a rare neurological disorder that can paralyze its victims, the government announced on Friday.
The patients -- all 17 or 18 years old -- developed Guillain-Barre Syndrome, or GBS, after receiving Sanofi's Menactra vaccine, which was approved for sale in January. All are recovering or have recovered, officials said.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!